Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $606000.0.

  • Cartesian Therapeutics' Depreciation & Amortization (CF) rose 11188.81% to $606000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 20277.48%. This contributed to the annual value of $1.2 million for FY2024, which is 3653.62% up from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Depreciation & Amortization (CF) is $606000.0, which was up 11188.81% from $589000.0 recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $1.2 million for Q1 2025, and its period low was $176000.0 during Q2 2023.
  • Its 5-year average for Depreciation & Amortization (CF) is $362315.8, with a median of $305000.0 in 2021.
  • Per our database at Business Quant, Cartesian Therapeutics' Depreciation & Amortization (CF) crashed by 4898.55% in 2023 and then skyrocketed by 53169.4% in 2025.
  • Cartesian Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $401000.0 in 2021, then tumbled by 39.9% to $241000.0 in 2022, then rose by 12.86% to $272000.0 in 2023, then soared by 78.68% to $486000.0 in 2024, then grew by 24.69% to $606000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $606000.0 for Q3 2025, versus $589000.0 for Q2 2025 and $1.2 million for Q1 2025.